Kuros Biosciences 

Kuros Biosciences AG operates as a biopharmaceutical firm, concentrating on the commercialization and advancement of products designed for tissue repair and bone regeneration. Its operations span the United States, the European Union, and international markets. The company's business is structured across three primary segments: Medical Devices, Pharmaceuticals, and its Legacy Portfolio. Within its orthobiologics pipeline, Kuros offers MagnetOs Granules and MagnetOs Putty, approved for use in both the EU and US to address orthopedic, spinal, and dental conditions. Furthermore, its fibrin/PTH orthobiologics line includes KUR-111, which has successfully concluded Phase 2b clinical trials for tibial plateau fractures. Another product, KUR-113, has similarly finished Phase 2b trials for tibial shaft fractures and is currently undergoing Phase II trials for spinal interbody fusion. The company's sealant offerings feature Neuroseal, a synthetic tissue sealant available in the EU and US, engineered to prevent cerebrospinal fluid leakage after cranial or spinal surgical procedures. Kuros Biosciences also maintains a collaborative partnership with Checkmate Pharmaceuticals LLC for the development of CYT003, targeting oncological treatments. The corporate headquarters of the company are located in Schlieren, Switzerland.